Recent Clinical Trials of Proprotein Convertase Subtilisin-Kexin (PCSK) Type 9 Inhibitors in Coronary Artery Disease

Publisher： Nova Science Publishers, Inc.

ISSN： 1556-4002

Source： World Heart Journal, Vol., Iss., 2017-01, pp. : 25-28

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Editorial 2.Proprotein Convertase Subtilisin/Kexin Type 9（PCSK9）Inhibitors

By  

World Heart Journal, Vol. , Iss. , 2015-04 ,pp. : 17-24

Nova Science Publishers, Inc.

Access to resources Recommend Favorite

Proprotein Convertase Subtilisin-Kexin (PCSK) Type 9 Inhibitors with Reference to Risk of Diabetes

By  

World Heart Journal, Vol. , Iss. , 2017-01 ,pp. : 19-24

Nova Science Publishers, Inc.

Access to resources Recommend Favorite

Proprotein Convertase Subtilisin Kexin 9 (PCSK9) and Lipoprotein Metabolism in Relation to Adverse Birth Outcome and Future Cardiometabolic Risk

By  

World Heart Journal, Vol. , Iss. , 2016-07 ,pp. : 41-46

Nova Science Publishers, Inc.

Access to resources Recommend Favorite

Proprotein Convertase Subtilisin Kexin 9 (PCSK9) and Lipoprotein Metabolism in Relation to Adverse Birth Outcome and Future Cardiometabolic Risk

By  

World Heart Journal, Vol. , Iss. , 2016-04 ,pp. : 13-18

Nova Science Publishers, Inc.

Access to resources Recommend Favorite

PCSK9 and Lipoprotein Metabolism

By  

World Heart Journal, Vol. , Iss. , 2016-07 ,pp. : 42-41

Nova Science Publishers, Inc.

Access to resources Recommend Favorite